Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI

Collaboration aims to enhance bioavailability and support clinical advancement of Clearmind’s lead MEAI candidate for addiction-related and other ...